Ra Biotech Ltd

Point of care (POC) diagnostic market is expected to be UD$50.6 billion by 2025 @ CAGR of 11.4%. With COVID pandemic, the demand for more innovative diagnostics solutions is ever increasing. The need is for more rapid and accurate results, whilst minimising the need for complex sample handling. POC diagnostic tests can offer all the benefits including digital integration via cloud network communications.

POC diagnostic tests are dominated by using antibodies as the recognition bio-receptor. Antibodies do work and has for years. But for small molecular targets, antibodies do suffer from specific binding. This is where aptamers can shine. There has been considerable academic research in developing aptamer based biosensors but none been commercialised thus far. The limiting factor we believe is the lack of devoted effort into building biosensors around the unique physiochemical properties of single stranded oligonucleotides. Aptamers deserve to stand on their own and not as an antibody replacement entity.

We at Ra Biotech believe that our knowledge and experience with developing aptamers will lead to the commercialisation of total diagnostics solutions using aptamers as the primary bio-receptor. We have over a decade of R&D experience with aptamers and demonstrable assays that can work in an analytical laboratory setting and portable infield testing capability.